Home » Market News » DirectorsTalk Highlights » Dr Miriam Stoppard on Lupus
Immupharma Plc

Dr Miriam Stoppard on Lupus

Lupus isn’t that common but when it strikes it can be very ­serious, even life-threatening. The story of the singer and ­actress Selena Gomez is a case in point.

All lupus sufferers will be grateful to her because she’s increased awareness of this often neglected condition.

Lupus (systemic lupus erythematosus, SLE), is a disease that causes collagen inflammation. As collagen provides the scaffolding for all our organs it can show up anywhere.

Few AIM-listed drug development companies have late-stage clinical assets in the pipeline, ImmuPharma plc (LON:IMM) is an exception. The Company’s lead compound, Lupuzor™, a potential treatment for Lupus, has completed Phase 3 trial of dosing patients across the US, Europe and Mauritius with top line results announced.

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.